Purple Biotech Forms Scientific Advisory Board to Drive CAPTN-3 Tri-Specific Antibody Platform

Purple Biotech ( (PPBT) ) has issued an update.

On April 23, 2026, Purple Biotech announced it has established a Scientific Advisory Board made up of leading experts in T-cell and NK-cell biology, tumor immunology, and clinical oncology to guide development of its CAPTN-3 tri-specific antibody platform. The SAB includes clinicians and scientists with direct experience in bringing first-in-class T-cell engager therapies such as tebentafusp and blinatumomab to market, strengthening the company’s translational capabilities as CAPTN-3 lead candidates IM1240 and IM1305 advance from preclinical work toward clinical-stage development.

By concentrating expertise in NK and T-cell engager science and early-phase oncology trials, the board is expected to sharpen Purple Biotech’s development strategy and trial design in highly competitive solid-tumor and hematologic markets. The move underpins the company’s ambition to differentiate CAPTN-3 via tumor-localized, conditionally activated immune engagement, potentially broadening its therapeutic window versus conventional T-cell engagers and reinforcing its positioning in the fast-evolving cancer immunotherapy landscape.

The most recent analyst rating on (PPBT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.

Spark’s Take on PPBT Stock

According to Spark, TipRanks’ AI Analyst, PPBT is a Neutral.

The score is held down primarily by weak financial performance (minimal revenue, widening losses, and continued cash burn alongside a shrinking equity base). Technicals are also bearish with negative momentum and price below key moving averages, only partially offset by oversold signals. Valuation contributes little support due to unprofitability and no dividend data.

To see Spark’s full report on PPBT stock, click here.

More about Purple Biotech

Purple Biotech Ltd., headquartered in Rehovot, Israel, is a clinical-stage biotech company focused on next-generation cancer immunotherapies that aim to maximize anti-tumor efficacy while minimizing toxicity. Its lead CAPTN-3 platform comprises masked tri-specific antibodies that target tumor antigens and engage both T cells and NK cells, with lead candidates IM1240 moving toward the clinic and IM1305 in preclinical development, alongside additional partnered-or-investment-dependent assets CM24 and NT219.

Average Trading Volume: 14,313

Technical Sentiment Signal: Strong Sell

Current Market Cap: $6.2M

See more data about PPBT stock on TipRanks’ Stock Analysis page.